Business Wire

ArtMajeur by YourArt: a Merger Boosted by AI

Share

The international platform that already handles 137,000 artists and over 3.5 million works of art, is using brand new AI tools to assist artists (in creating and selling their works), and art lovers (in finding and purchasing works).

Only six months after Artmajeur was acquired by Maurice Lévy, founder of YourArt, and with the total merging of all operations, the new ArtMajeur by YourArt platform is now equipped to become the favoured destination for artists, galleries, collectors, and all art lovers. Operating in 78 countries including France, the USA, England and Japan, its enormous scope makes it a vital player in the global online art market.

ArtMajeur by YourArt brings together the best of two entities. The power and impact of Artmajeur means that it attracts almost 800,000 single visits every month, and is able to offer a solid marketplace, built up over the years, where artists and buyers can meet. Now, the technological leadership of YourArt and the major advances it has made in artificial intelligence can be put to use by all artists and users of the platform. The same goes for its know-how in matters of content (curation by art experts, publications, videos, social media…) and its ability to provide its artists with visibility beyond the digital platform, by means of visits to galleries, exhibitions and meetings.

With artificial intelligence at its core, ArtMajeur by YourArt – one of the foremost online art platforms in the world – provides a unique service for artists and art lovers. Its AI assistant –Iris – was developed by its R&D staff and has specific dedicated features:

  • For artists, YourCreation is one of the first applications to draw on the new APIs for image generation. It enables artists to generate images from prompts and reference images they themselves have chosen. The results are aimed at stimulating the creative process and may be used by the artists in any way they wish. Also, YourAssistant enables them to use AI to enrich the creative process: by importing the image of a work of art, they can obtain immediate responses (opinions, references, advice…).
  • For art lovers, YourGift (finding a suitable work of art), YourPortrait (finding out about one's artistic tastes) and YourMatch (presenting a coup de cœur) provide easy access to the whole database. They make it possible for art lovers to choose the works that best correspond to their own tastes from among the thousands of works of art on the platform.

Furthermore, there is a new section on the platform called “AI & Art.” This details the AI features and also presents how ArtMajeur by YourArt sees the place of AI in art. It lays out its ethical convictions and looks at the current debate on this important and sensitive issue.

Over the next few months, ArtMajeur by YourArt will be adding to the AI features, thereby developing the platform even further, providing more opportunities for art lovers to discover works of art, and increasing sales for artists.

ArtMajeur by YourArt: the key figures

A major platform
3.5 million works of art, 137,000 artists, 750 galleries.

Recent sales: the top 3
47,800€ for Floris mit Frosch und EI by Jean Lawa.
13,965€ for two works by Viktor Sheleg.
12,680€ for Lovely Seal by Irena Aizen.

AI data
90.4% of reactions to all the tests carried out have been positive.
71.9% of users find the analyses, descriptions and suggestions relevant.
Users come from 40 different countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250603466296/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release

- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc

Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse

Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø

IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release

IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the

HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 14:00:00 CEST | Press release

Pivotal Study Advances to Establish Histotripsy as a Non-Thermal, Surgery-Free Alternative to Destroy and Liquefy Kidney Tumors HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison

Norwegian Tech Firm Builds Military Command Center in 24 Hours6.6.2025 13:45:00 CEST | Press release

Norwegian technology provider Cyviz has successfully developed a fully mobile and ballistic-proof command center - designed, configured, and made operational in just 24 hours. The solution was showcased during a military exercise led by the Dutch Ministry of Defence and has already sparked interest from NATO members and civil protection agencies across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606640770/en/ Cyviz demonstrates rapid deployment capability with a mobile, container-based control room for defense and crisis response Cyviz and its partners constructed the command room inside a 14-ton container designed for transport on standard military vehicles and resistant to machine gun fire. The unit was deployed at a military base in the Netherlands, where Cyviz was tasked with delivering a fully functional command-and-control environment, under strict time constraints and in a high-stakes simulation. "You do

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye